Results of a new survey detailing the attitudes of consumers toward direct-to-consumer print and television advertising for pharmaceuticals have been released by the Food and Drug Administration's Division of Drug Marketing, Advertising and Communications.
The 58-question survey, "Attitudes and Behaviors Associated with Direct-to-Consumer (DTC) Promotion of Prescription Drugs," was conducted over the phone with the cooperation of 1,081 consumers. An additional follow-up written survey, the results of which had not been released at press time, looked at consumer recognition of 12 direct-to-consumer advertising campaign.
The survey revealed that 30% of consumers who have seen a doctor in the last three months, and 39% of consumers who have not seen a doctor in the last month read none of the fine print information in print DTC drug ads. However, 70% of consumers who were "especially interested" in an advertised drug would read all of the information as opposed to the 2% to 3% who would read none of the fine print.
Advertising influenced roughly half the respondents to look for more information about the drug advertised or their personal health, but only 27% of those who had seen a doctor in the last three months and 8% of those who had not seen a doctor in the last three months were ever prompted by an advertisement to "ask a doctor about a medical condition or illness of [their] own that they had not talked to a doctor about before."
Full results of the survey, which also looked at how consumers perceived their doctors' reactions to queries about advertised prescription drugs, are available at www.fda.gov/cder/ddmac/dtcindex.htm#Q1. PR
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
March 14th 2025New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.